AKAO/PRTK Cut my losses in both a while ago, and am especially glad I did with AKAO. Plazomycin approval in cUTI not keeping it from issuing going concern language, as that market is apparently too small/competitive. Still have a small position in PRTK, which fared better in its AdCom just now, having gotten substantial majority votes in favor of approval for ABSSSI and CABP. I'll likely bail on any pop (still halted), as it's an improvement in only a couple of strains, and not by a whole lot. Compliance is likely to be better/easier, but that doesn't impress payers much. So like most antibiotics launches, I'd expect this one to be slow.
That said, trading only slightly over cash and with over 18% short interest, this depressed pup could pop farther than expected on this news. Hoping for $13+ within a few days. If analysts get behind it a bit, that could happen. If not, half that, my guess.
Cheers, Tuck |
